MARKET

CAMP

CAMP

Camp4 Therapeutics Corp.
NASDAQ
1.860
-0.160
-7.92%
After Hours: 1.900 +0.04 +2.14% 19:56 05/14 EDT
OPEN
2.100
PREV CLOSE
2.020
HIGH
2.100
LOW
1.800
VOLUME
185.73K
TURNOVER
--
52 WEEK HIGH
12.30
52 WEEK LOW
1.610
MARKET CAP
37.50M
P/E (TTM)
-0.7005
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Remains a Buy on CAMP4 Therapeutics Corporation (CAMP)
TipRanks · 15h ago
William Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)
TipRanks · 17h ago
Camp4 Therapeutics Q1 EPS $(0.62) Up From $(26.57) YoY, Sales $858.00K
Benzinga · 1d ago
CAMP4 REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS
Reuters · 1d ago
Press Release: CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
Dow Jones · 1d ago
Weekly Report: what happened at CAMP last week (0505-0509)?
Weekly Report · 2d ago
Pre-Market Most Active for May 6, 2025 : TSLL, CAMP, PLTR, SQQQ, TQQQ, WRD, BABA, HIMS, NIO, UMC, BEKE, F
NASDAQ · 05/06 12:28
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 05/06 12:08
More
About CAMP
More
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Recently
Symbol
Price
%Change

Webull offers Camp4 Therapeutics Corp. stock information, including NASDAQ: CAMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAMP stock methods without spending real money on the virtual paper trading platform.